Our pipeline strategy is to build a risk-controlled clinical-stage pipeline with an exclusive focus on novel or highly differentiated biologics.

  • On-going

  • Planned

Uliledlimab (CD73 antibody)

More info
  • Indication
  • Phase 1
  • Phase 2
  • Phase 3
  • BLA

NSCLC

1L combo with chemo and CPI

Upon the receipt of the investigational new drug (IND) approval, I-Mab plans to initiate the triplet study for uliledlimab in combination with chemotherapy and checkpoint inhibitors in newly diagnosed patients with advanced NSCLC in the second half of 2024.

Givastomig (Claudin 18.2 x 4-1BB bispecific antibody)

More info
  • Indication
  • Phase 1
  • Phase 2
  • Phase 3
  • BLA

GC/GEJ/EAC, PDAC

2L monotherapy

GC/GEJ/EAC

1L combo with chemo and CPI

Ragistomig (PD-L1 x 4-1BB bispecific antibody)

More info
  • Indication
  • Phase 1
  • Phase 2
  • Phase 3
  • BLA

Solid Tumors

Monotherapy

Abbreviations

  • 1L = First line
  • 2L = Second line
  • CPI = Checkpoint inhibitor
  • EAC = Esophageal adenocarcinoma
  • GC = Gastric cancer
  • GEJ = Gastro-esophageal junction adenocarcinoma
  • NSCLC = Non-small cell lung cancer
  • PDAC = Pancreatic ductal adenocarcinoma

Pipeline as of April 2024